The increase in research and development
funds for drug discovery followed by growing awareness of kidney-related
disorders, and diabetes are the major factors driving the expansion of the
global diabetic nephropathy market.
Diabetes is a disease defined by high blood
sugar level, caused by inappropriate functioning of the pancreas (the organ
which secretes insulin in the body). Nephropathy means kidney
impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys
caused by diabetes.
It is a disease which affects the kidney
glomerulus and one of the most major issues for diabetic patients. Not only the
person with diabetes has to undergo kidney impairment, but also the
acute cases of diabetic nephropathy could lead to kidney miscarriage. The
disease affects the kidneys in a way that makes it futile. Progressive growth
in proteinuria and failure in renal function, hypertension, and high risk of
cardiovascular disease are the major side effects of chronic diabetic
nephropathy. Blood pressure (BP) control is necessary in minimizing the
progression of diabetic nephropathy. Irrespective of the agent used, lower
blood pressure in type II diabetics could slow down the start and progression
of diabetic nephropathy.
Request to Get the Sample Pages at:
On the basis of mode of treatment, the global
diabetic nephropathy market is segmented into disease modifying therapies and
others. Disease modifying therapies is further categorized into diuretics,
angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator,
angiotensin receptor blockers, renin inhibitors, calcium channel blockers,
connective tissue growth factor inhibitors, monocyte chemoattractant proteins
inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).
Make Enquiry Before Buying the
Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-nephropathy-market
Various government programs are spreading
cognizance about diabetes and related renal complications in North America. For
example, the National Kidney Disease Education Program (NKDEP) is one of the
most important programs organized by the U.S. government, for growing awareness
about the various kidney diseases.
Lack of complete therapeutic management for
diabetic nephropathy, longer approval time for drugs as well as, harsh
regulatory requirements are hampering the market growth of global diabetes
nephropathy market.
Some of the major competitors in the global
diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer
Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata
Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma
Corporation.
